Advisory Board

image-2

CTO Fiat Chrysler Automobiles
Read more

Harald Wester was born in Linz am Rhein, Germany. He obtained a Masters in Mechanical Engineering from Braunschweig University.

Mr. Wester started his professional career at Volkswagen AG in Wolfsburg, where he was General Manager of the Vehicle Research & New Concepts department from 1991 to 1995. Later that year, he joined Audi AG in Ingolstadt where he became Program Manager for the A2 models & Special Vehicles, a position that he held until October 1998.

Subsequently, he joined Ferrari S.p.A. at Maranello as Director of Product Development, where he remained until January 2002.

Mr. Wester was then hired by Magna Steyr AG, Magna AG (Graz, Vienna) as Group President Engineering and Chief Technical Officer (Research, Development and Technologies).

In 2004, he joined the Fiat Group where he took on the role of Chief Technical Officer of Fiat Group Automobiles. He was appointed Chief Technology Officer for the Fiat Group in September 2007. In addition to this role, in August 2008 he was appointed Chief Executive Officer of Maserati S.p.A. (until May 2016), in January 2009 Chief Executive Officer of Abarth & C. S.p.A. (until 2013), and in January 2010 Chief Executive Officer of Alfa Romeo Automobiles (until May 2016). Harald Wester was appointed Chief Technology Officer of FCA and member of the Group Executive Council (GEC) on September 1, 2011. 2013).

image-3

President Dyson Inc.
Read more

M. Conze has served as President of Dyson from Fall 2010 until autumn 2017. Previous to this role, M. Conze was a General Manager in Procter&Gamble’s Global Beauty Care business and a Managing Director of P&G’s German, Austrian and Swiss beauty business. M. Conze joined P&G in 1993 and has held ascending leadership positions as brand manager, marketing director and managing director in the company’s global, European, US and Asian operations. He holds a Bachelor of Business Administration degree (summa cum laude) from Columbus State University and has lectured on leadership and related topics internationally.

image-4

Business Consultant 

Read more

Now working as an independent business consultant & interior designer, B. Conze has a business background having served as an international marketing executive within the beauty and travel industry. She worked at L’Oreal, Düsseldorf, last as head of consultancy/ trade marketing before taking on the role as Marketing Manager Eurotunnel, France, launching the Le Shuttle cross channel car service into the German market. She finally successfully developed new business ventures for Hilton International, London, where she was responsible for new product development for all Hilton International properties worldwide. B. Conze holds a master’s degree in business administration from Cologne University. She started a second career in 2000 by studying interior design staying at home raising two children whilst living in England, the US, Switzerland, France, China and recently in Germany. She obtained her diploma in Interior Design from Rhodec International, London, in March 2004.

hjpw

Chair of Pharm. Radiochem., TUM

Read more

Study of Chemistry, University of Cologne, Diploma (1992) in Radiochemistry, Nuclear Research Center Juelich GER; Doctoral Thesis (1996), Ph.D., Radiopharmaceutical Chem., Research Center Juelich; Scientific Assistant (1996-97) & Research associate (1998-2003), Department of Nucl.Med., Technical University Munich (TUM); in 2003 several Offers (Associate and Full Professorships) by US and German Universities; Professor (C3) of Radiopharmaceutical Chemistry (2004-2010), TUM, Faculty of Medicine, Dept. of Nucl.Med., coappointment at the Faculty of Chemistry, since 2010 Full Professor (W3) for Pharmaceutical Radiochemistry at the TUM, 1st full appointment at the Faculty of Chemistry, 2nd full appointment at the Faculty of Medicine. Foundation of SCINTOMICS GmbH in 2006, CEO (2006-2015).Research Focus: Development of specific molecular probes for the non-invasive imaging of diseases, new strategies for production of radiopharmaceuticals, radionuclide therapy, tissue selective targeting of imaging probes and therapeutic compounds, transfer of genomic and proteomic information into new imaging methods.
>390 Publications, h-factor: 64 (03.2018).